Ad-hoc | 14 April 2011 08:32
4SC AG / Key word(s): Alliance
14.04.2011 08:32
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Planegg-Martinsried, Germany, 14 April, 2011 - 4SC AG (Frankfurt, Prime
Standard: VSC) and Yakult Honsha Co.; Ltd. (Tokyo: 2267) today announced
the grant of an exclusive license by 4SC to Yakult Honsha for the
development and commercialisation of resminostat in Japan.
4SC will receive an upfront payment from Yakult Honsha of EUR6 million and
up to EUR127 million payable upon achieving specified milestones including
clinical and regulatory events in Japan. In addition to milestone payments
Yakult will pay 4SC double-digit royalties linked to product sales of
resminostat, which will also include the API costs. 4SC will be the
exclusive supplier of resminostat to Yakult Honsha. Yakult Honsha will be
responsible for all development and clinical requirements in Japan for
resminostat in hepatocellular carcinoma, colorectal cancer and other chosen
oncology indications.
---------------------------------------------------------------------------
Information and Explaination of the Issuer to this News:
Telephone Conference
4SC will host a telephone conference at 3:00 pm CET (9:00 am EST) today to
inform about the agreement with Yakult Honsha.
To participate in the telephone conference, please use the following data:
Date: 14 April 2011
Time: 3:00 pm CET (9:00 am EST)
Dial-in numbers:
0800 10 12 072 (Germany)
0800-358-0886 (UK)
1-877-941-2930 (USA)
+49 (0) 6958 999 0804 (other countries)
Conference ID: 4433039
Approximately two hours after the live telephone conference, an audio
replay of the conference will be available on the 'investors' section of
www.4sc.com.
About Yakult Honsha
Yakult Honsha is a leading Japanese company focused on the development and
marketing of pharmaceuticals, foods, beverages, and cosmetics. As for
pharmaceutical business Yakult Honsha has an emerging presence in oncology.
For more information on Yakult, visit:
http://www.yakult.co.jp/english/index.html or view the following company
profile
http://www.yakult.co.jp/english/pdf/profile2010-2011.pdf
About 4SC
4SC AG (ISIN DE0005753818) discovers and develops targeted small molecules
for autoimmune and cancer indications. Vidofludimus (4SC-101), an IL-17
inhibitor, is currently in Phase II development in rheumatoid arthritis and
inflammatory bowel disease (IBD), for which positive results from a Phase
IIa study were recently reported. The company's lead oncology compound,
resminostat (4SC-201), an oral pan-histone deacetylase (HDAC) inhibitor, is
in Phase II trials in hepatocellular carcinoma, Hodgkin's lymphoma and
KRAS-mutant colorectal cancer. Two further oncology compounds, 4SC-203 and
4SC-205, are in Phase I studies. 4SC develops drug candidates until
proof-of-concept in order to generate value creating partnerships with the
pharmaceutical industry in return for advance and milestone payments as
well as royalties.
Founded in 1997, 4SC has 94 employees and has been listed on the Prime
Standard of the Frankfurt Stock Exchange since December 2005.
For further information, please visit www.4sc.com.
Legal Note
This document may contain projections or estimates relating to plans and
objectives relating to our future operations, products, or services; future
financial results; or assumptions underlying or relating to any such
statements; each of which constitutes a forward-looking statement subject
to risks and uncertainties, many of which are beyond our control. Actual
results could differ materially, depending on a number of factors.
For more information please contact:
4SC
Yvonne Alexander
Investor & Public Relations
Tel.: +49 (0) 89 70 07 63 0
MC Services (Europe)
Raimund Gabriel
Tel.: +49 (0) 89 21 02 28 40
The Trout Group (USA)
Chad Rubin
Tel.: +1 646 378 2947
Yakult Honsha Co., Ltd.
Tel: +81-3-3574-8920 (Japanese)
E-mail: publ-of1@yakult.co.jp (Japanese and English)
14.04.2011 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: 4SC AG
Am Klopferspitz 19a
82152 Martinsried
Deutschland
Phone: +49 (0)89 7007 63-0
Fax: +49 (0)89 7007 63-29
E-mail: public@4sc.com
Internet: www.4sc.de
ISIN: DE0005753818
WKN: 575381
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------